Cell Reports-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向：molecular biology 经验分享：with editor已经8天了，什么原因呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209402, encodeId=0a0612094023b, content=偏重的研究方向：肿瘤 经验分享：投稿5天后with editor，3天后送审，5周被拒，2个reviewer挺犀利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc73120115, createdName=853561971, createdTime=Thu Apr 07 23:13:42 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿， 20190426 with editor， 20190504 review， , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207210, encodeId=5ece120e21004, content=太慢了，审稿结束编辑都要搞一个半月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a3ae5503264, createdName=ms6000000684182217, createdTime=Wed Mar 30 14:32:34 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200350, encodeId=b84712003500e, content=？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b23462159, createdName=130a765fm69暂无昵称, createdTime=Mon Mar 07 21:02:37 CST 2022, time=2022-03-07, status=1, ipAttribution=)]

2022-06-18 ms6000001341584296

审稿速度:1.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤
经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。

200 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向：molecular biology 经验分享：with editor已经8天了，什么原因呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209402, encodeId=0a0612094023b, content=偏重的研究方向：肿瘤 经验分享：投稿5天后with editor，3天后送审，5周被拒，2个reviewer挺犀利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc73120115, createdName=853561971, createdTime=Thu Apr 07 23:13:42 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿， 20190426 with editor， 20190504 review， , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207210, encodeId=5ece120e21004, content=太慢了，审稿结束编辑都要搞一个半月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a3ae5503264, createdName=ms6000000684182217, createdTime=Wed Mar 30 14:32:34 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200350, encodeId=b84712003500e, content=？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b23462159, createdName=130a765fm69暂无昵称, createdTime=Mon Mar 07 21:02:37 CST 2022, time=2022-03-07, status=1, ipAttribution=)]

2022-06-22 ms1000001147318258

审稿速度:1.0 | 投稿命中率:50.0
经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。
个人感觉期刊是很有效率和节奏的，值得推荐投稿。

183 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向：molecular biology 经验分享：with editor已经8天了，什么原因呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209402, encodeId=0a0612094023b, content=偏重的研究方向：肿瘤 经验分享：投稿5天后with editor，3天后送审，5周被拒，2个reviewer挺犀利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc73120115, createdName=853561971, createdTime=Thu Apr 07 23:13:42 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿， 20190426 with editor， 20190504 review， , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207210, encodeId=5ece120e21004, content=太慢了，审稿结束编辑都要搞一个半月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a3ae5503264, createdName=ms6000000684182217, createdTime=Wed Mar 30 14:32:34 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200350, encodeId=b84712003500e, content=？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b23462159, createdName=130a765fm69暂无昵称, createdTime=Mon Mar 07 21:02:37 CST 2022, time=2022-03-07, status=1, ipAttribution=)]

2022-05-27 sunyong_97

偏重的研究方向：molecular biology
经验分享：with editor已经8天了，什么原因呢？

146 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向：molecular biology 经验分享：with editor已经8天了，什么原因呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209402, encodeId=0a0612094023b, content=偏重的研究方向：肿瘤 经验分享：投稿5天后with editor，3天后送审，5周被拒，2个reviewer挺犀利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc73120115, createdName=853561971, createdTime=Thu Apr 07 23:13:42 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿， 20190426 with editor， 20190504 review， , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207210, encodeId=5ece120e21004, content=太慢了，审稿结束编辑都要搞一个半月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a3ae5503264, createdName=ms6000000684182217, createdTime=Wed Mar 30 14:32:34 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200350, encodeId=b84712003500e, content=？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b23462159, createdName=130a765fm69暂无昵称, createdTime=Mon Mar 07 21:02:37 CST 2022, time=2022-03-07, status=1, ipAttribution=)]

2022-07-01 franky45

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：转录因子
经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。

139 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向：molecular biology 经验分享：with editor已经8天了，什么原因呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209402, encodeId=0a0612094023b, content=偏重的研究方向：肿瘤 经验分享：投稿5天后with editor，3天后送审，5周被拒，2个reviewer挺犀利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc73120115, createdName=853561971, createdTime=Thu Apr 07 23:13:42 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿， 20190426 with editor， 20190504 review， , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207210, encodeId=5ece120e21004, content=太慢了，审稿结束编辑都要搞一个半月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a3ae5503264, createdName=ms6000000684182217, createdTime=Wed Mar 30 14:32:34 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200350, encodeId=b84712003500e, content=？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b23462159, createdName=130a765fm69暂无昵称, createdTime=Mon Mar 07 21:02:37 CST 2022, time=2022-03-07, status=1, ipAttribution=)]

2022-05-20 术士话剧

偏重的研究方向：骨生物学
经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？

69 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向：molecular biology 经验分享：with editor已经8天了，什么原因呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209402, encodeId=0a0612094023b, content=偏重的研究方向：肿瘤 经验分享：投稿5天后with editor，3天后送审，5周被拒，2个reviewer挺犀利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc73120115, createdName=853561971, createdTime=Thu Apr 07 23:13:42 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿， 20190426 with editor， 20190504 review， , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207210, encodeId=5ece120e21004, content=太慢了，审稿结束编辑都要搞一个半月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a3ae5503264, createdName=ms6000000684182217, createdTime=Wed Mar 30 14:32:34 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200350, encodeId=b84712003500e, content=？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b23462159, createdName=130a765fm69暂无昵称, createdTime=Mon Mar 07 21:02:37 CST 2022, time=2022-03-07, status=1, ipAttribution=)]

2022-04-07 853561971

偏重的研究方向：肿瘤
经验分享：投稿5天后with editor，3天后送审，5周被拒，2个reviewer挺犀利的

70 0

[GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向：molecular biology 经验分享：with editor已经8天了，什么原因呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209402, encodeId=0a0612094023b, content=偏重的研究方向：肿瘤 经验分享：投稿5天后with editor，3天后送审，5周被拒，2个reviewer挺犀利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc73120115, createdName=853561971, createdTime=Thu Apr 07 23:13:42 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿， 20190426 with editor， 20190504 review， , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207210, encodeId=5ece120e21004, content=太慢了，审稿结束编辑都要搞一个半月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a3ae5503264, createdName=ms6000000684182217, createdTime=Wed Mar 30 14:32:34 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200350, encodeId=b84712003500e, content=？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b23462159, createdName=130a765fm69暂无昵称, createdTime=Mon Mar 07 21:02:37 CST 2022, time=2022-03-07, status=1, ipAttribution=)]

2021-01-12 疯狂的丫头0731

审稿速度:2.0 | 投稿命中率:25.0
经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。

228 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向：molecular biology 经验分享：with editor已经8天了，什么原因呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209402, encodeId=0a0612094023b, content=偏重的研究方向：肿瘤 经验分享：投稿5天后with editor，3天后送审，5周被拒，2个reviewer挺犀利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc73120115, createdName=853561971, createdTime=Thu Apr 07 23:13:42 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿， 20190426 with editor， 20190504 review， , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207210, encodeId=5ece120e21004, content=太慢了，审稿结束编辑都要搞一个半月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a3ae5503264, createdName=ms6000000684182217, createdTime=Wed Mar 30 14:32:34 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200350, encodeId=b84712003500e, content=？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b23462159, createdName=130a765fm69暂无昵称, createdTime=Mon Mar 07 21:02:37 CST 2022, time=2022-03-07, status=1, ipAttribution=)]

2019-05-05 ms2638880249707848

20190424投稿，
20190426 with editor，
20190504 review，

3 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向：molecular biology 经验分享：with editor已经8天了，什么原因呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209402, encodeId=0a0612094023b, content=偏重的研究方向：肿瘤 经验分享：投稿5天后with editor，3天后送审，5周被拒，2个reviewer挺犀利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc73120115, createdName=853561971, createdTime=Thu Apr 07 23:13:42 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿， 20190426 with editor， 20190504 review， , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207210, encodeId=5ece120e21004, content=太慢了，审稿结束编辑都要搞一个半月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a3ae5503264, createdName=ms6000000684182217, createdTime=Wed Mar 30 14:32:34 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200350, encodeId=b84712003500e, content=？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b23462159, createdName=130a765fm69暂无昵称, createdTime=Mon Mar 07 21:02:37 CST 2022, time=2022-03-07, status=1, ipAttribution=)]

2022-03-30 ms6000000684182217

太慢了，审稿结束编辑都要搞一个半月

51 0

[GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222887, encodeId=cdf6122288e78, content=偏重的研究方向：molecular biology 经验分享：with editor已经8天了，什么原因呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Fri May 27 22:22:35 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209402, encodeId=0a0612094023b, content=偏重的研究方向：肿瘤 经验分享：投稿5天后with editor，3天后送审，5周被拒，2个reviewer挺犀利的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc73120115, createdName=853561971, createdTime=Thu Apr 07 23:13:42 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851184, encodeId=274685118445, content=20190424投稿， 20190426 with editor， 20190504 review， , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94ad5414086, createdName=ms2638880249707848, createdTime=Sun May 05 11:18:05 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207210, encodeId=5ece120e21004, content=太慢了，审稿结束编辑都要搞一个半月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a3ae5503264, createdName=ms6000000684182217, createdTime=Wed Mar 30 14:32:34 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200350, encodeId=b84712003500e, content=？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b23462159, createdName=130a765fm69暂无昵称, createdTime=Mon Mar 07 21:02:37 CST 2022, time=2022-03-07, status=1, ipAttribution=)]

2022-03-07 130a765fm69暂无昵称

？

75 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务